



## News Release

Jennifer Gooding, Director of Media and Publications  
O: 512.322.5637 C: 512.961.8197  
[jgooding@austinchamber.com](mailto:jgooding@austinchamber.com)  
[www.austinchamber.com](http://www.austinchamber.com)

### *Biopharmaceutical Company Xeris Joins the Growing Ranks of California Businesses Relocating in Austin*

May 5, 2011 — Xeris – an early-stage biopharmaceutical company developing patient-friendly injectables to treat endocrine and metabolic diseases – announced their relocation from Larkspur, California to Austin, Texas.

Xeris joins a growing number of life science companies choosing Austin as their home. In 2010, Hangar Orthopedic moved its headquarters to Austin. They were joined by Pioneer Surgical, Viral Genetics, Vermillion, Owens & Minor, and Pain Therapeutics who also announced Austin locations that year.

“We are pleased to add Xeris to the growing list of life science companies calling Austin home,” said the Chamber’s Senior Vice President of Economic Development, Dave Porter. “The life science industry is one of our fastest growing industry sectors, employing thousands of Central Texans.”

The Chamber, through its main economic development initiative, Opportunity Austin, assisted Xeris in selecting Austin by helping facilitate key introductions to leaders in Austin’s life science companies as well as University of Texas staff.

Dr. John Kinzell, CEO of Xeris, cited the often-heard reasons for California companies relocating to Central Texas: a business-friendly climate and lower cost of doing business. Kinzell said after evaluating six states and nine metro areas, he selected Texas because of the quality of the state’s life science cluster, and he chose Austin because of its continual ranking as one of the top entrepreneurial cities in the U.S. and the presence of top research university UT Austin.

“In the end, I came to believe that Austin had the quality of life, cost of living and growing biotech cluster that would allow our company to attract C-suite executives and scientists from both coasts,” said Kinzell.

Staff levels will likely double in the following two years as Xeris develops products in its portfolio that will target osteoporosis, infertility and autoimmune diseases.

The company was recently admitted to the Austin Technology Incubator and is focusing on commercialization of their lead product: the Glucagon Rescue Pen™ (GRP™). This product is being developed to offer an improved method for emergency treatment of severe hypoglycemic events (dangerously low blood sugar) in diabetics.

#### *About the Chamber*

*The mission of the Austin Chamber of Commerce is to provide leadership that facilitates the creation of a prosperous regional economy and effective advocacy for its members. For more information about the Austin Chamber of Commerce visit [austinchamber.com](http://austinchamber.com).*

*(MORE)*

*(XERIS, PAGE 2)*

### ***About Opportunity Austin***

*Opportunity Austin is the Austin Chamber of Commerce's five-year economic development initiative to foster sustainable growth through the creation of new jobs and increased payroll in the Central Texas region. For more information please visit [opportunityaustin.com](http://opportunityaustin.com).*

### ***About Xeris***

Xeris develops patient-friendly injectables based on its XeriJect™ and XeriSol™ formulation and delivery platforms. The company's products are ultra-low-volume, injectable bio-pharmaceuticals packaged in an auto-injector pen that patients and their caregivers can use at home or work. Bio-pharmaceuticals are the fastest growing category of therapeutics and are forecasted to be six of the top 10 drugs by 2014. The current paradigm of delivery requires nearly all of these drugs to be administered by injection or infusion, often in a clinical setting, decreasing compliance, increasing cost and providing a terrible patient experience. Xeris aspires to change this paradigm by developing ultra-low volume, ready-to-use bio-pharmaceuticals delivered through patient-friendly injectable devices, many of which would be self-administered in the comfort of the patient's home. Products built on Xeris' technologies would simplify administration and ease the pain of injections, improving the experience for hundreds of millions of patients. For more information, visit [www.xerispharma.com](http://www.xerispharma.com).

###